Researchers at Nagoya University in Japan have linked blood levels of N-acyl taurines, or NATs, to disease progression rates in amyotrophic lateral sclerosis patients. The discovery opens a fresh path for drug discovery by pointing to metabolic changes observed directly in patients rather than relying entirely on standard laboratory models.
How Blood Metabolites Reveal ALS Progression
A team of researchers led by Nagoya University researchers in Japan has identified a metabolic signal in the blood of people with amyotrophic lateral sclerosis that tracks how quickly the disease advances. The investigators found that blood levels of lipid-related signaling molecules called N-acyl taurines were elevated in individuals experiencing rapidly progressing forms of the condition. Furthermore, patients showing the highest concentrations of these molecules had shorter survival times.
N-acyl taurines are lipid-related signalling molecules that form part of the extended endocannabinoid system, a complex network that regulates nervous system function, inflammation, and metabolism. Rather than treating metabolic shifts merely as downstream consequences of motor neuron degeneration, the Nagoya team analyzed patient samples to uncover the drivers behind differing progression rates. “We therefore began by analysing patient blood samples to map metabolic changes and identify treatments suggested by the results,” said Professor Masahisa Katsuno.
From Patient Blood Samples to Experimental Testing
The research methodology moved systematically from clinical samples to cellular models and animal experiments. Investigators initially analyzed blood from a discovery cohort of 26 people with ALS alongside 10 healthy controls. They then followed this with a replication cohort involving 55 people with ALS and 25 healthy controls. All participants were Japanese and were recruited at Nagoya University Hospital.
An untargeted metabolomics screen highlighted NATs because their concentration correlated with patient survival and changes in the revised ALS Functional Rating Scale. Based on these metabolic clues, the team tested compounds against metabolic pathways identified through their patient analysis. The compound PF-04457845 emerged as a promising candidate because it inhibits FAAH, an enzyme involved in breaking down several lipid mediators. Administering this compound upregulated the extended endocannabinoid system, including NATs and N-acyl ethanolamines (NAEs), in the researchers’ models.
Testing PF-04457845 in Cellular and Animal Models
In laboratory experiments using patient-derived cells and motor neurons generated from patient-derived induced pluripotent stem cells, the compound reduced signs of motor neuron degeneration and showed effects on neurite preservation, demonstrating that the compound could protect vulnerable neuronal structures. To test translational potential, the investigators then tested the compound in SOD1^G93A ALS mice.
The study bridges distinct levels of scientific evidence by starting with metabolic changes observed directly in patients rather than relying primarily on laboratory models.
Addressing Limitations in Sporadic ALS Drug Discovery
Amyotrophic lateral sclerosis causes progressive loss of upper and lower motor neurons, leading to worsening muscle weakness and ultimately respiratory failure. Around 90-95 percent of ALS cases are sporadic rather than familial, meaning there is no known family history of the disease. That distinction matters for drug discovery. SOD1-based mouse models are widely used in ALS research and can reproduce important features of motor neuron degeneration and changes in glial cells. However, they do not necessarily reflect the full pathogenesis of sporadic ALS. The researchers acknowledge this as a limitation of their study. ALS also involves systemic metabolic changes, including altered glucose metabolism and a hypermetabolic state.
Rather than treating these changes simply as consequences of the disease, the Nagoya team asked whether they could contain clues to the mechanisms driving different rates of progression. The researchers propose that elevated NAT levels may represent a protective response by the body which is ultimately unable to compensate for the damage caused by the disease. That raises an important therapeutic question: rather than suppressing NATs, could increasing their levels help protect vulnerable nerve cells?
